Literature DB >> 25376024

Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.

Elizabeth A Miller1, Meredith R Spadaccia, Thomas Norton, Morgan Demmler, Ramya Gopal, Meagan O'Brien, Nathaniel Landau, Thomas W Dubensky, Peter Lauer, Dirk G Brockstedt, Nina Bhardwaj.   

Abstract

HIV-1 infection is characterized by myeloid dendritic cell (DC) dysfunction, which blunts the responsiveness to vaccine adjuvants. We previously showed that nonviral factors in HIV-seropositive plasma are partially responsible for mediating this immune suppression. In this study we investigated recombinant Listeria monocytogenes (Lm) vectors, which naturally infect and potently activate DCs from seronegative donors, as a means to overcome DC dysfunction associated with HIV infection. Monocyte-derived DCs were cocultured with plasma from HIV-infected donors (HIV-moDCs) to induce a dysregulated state and infected with an attenuated, nonreplicative vaccine strain of Lm expressing full length clade B consensus gag (KBMA Lm-gag). Lm infection stimulated cytokine secretion [interleukin (IL)-12p70, tumor necrosis factor (TNF)-α, and IL-6] and Th-1 skewing of allogeneic naive CD4 T cells by HIV-moDCs, in contrast to the suppressive effects observed by HIV plasma on moDCs on toll-like receptor ligand stimulation. Upon coculture of "killed" but metabolically active (KBMA) Lm-gag-infected moDCs from HIV-infected donors with autologous cells, expansion of polyfunctional, gag-specific CD8(+) T cells was observed. Reactivation of latent proviruses by moDCs following Lm infection was also observed in models of HIV latency in a TNF-α-dependent manner. These findings reveal the unique ability of Lm vectors to contend with dysregulation of HIV-moDCs, while simultaneously possessing the capacity to activate latent virus. Concurrent stimulation of innate and adaptive immunity and disruption of latency may be an approach to reduce the pool of latently infected cells during HIV infection. Further study of Lm vectors as part of therapeutic vaccination and eradication strategies may advance this evolving field.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25376024      PMCID: PMC4287309          DOI: 10.1089/AID.2014.0138

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  74 in total

1.  Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection.

Authors:  María Almeida; Miguel Cordero; Julia Almeida; Alberto Orfao
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

Review 2.  Targeting HIV latency: pharmacologic strategies toward eradication.

Authors:  Sifei Xing; Robert F Siliciano
Journal:  Drug Discov Today       Date:  2012-12-25       Impact factor: 7.851

3.  Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes.

Authors:  M V Rayevskaya; F R Frankel
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

5.  Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector.

Authors:  F R Frankel; S Hegde; J Lieberman; Y Paterson
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

6.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Authors:  Dirk G Brockstedt; Martin A Giedlin; Meredith L Leong; Keith S Bahjat; Yi Gao; William Luckett; Weiqun Liu; David N Cook; Daniel A Portnoy; Thomas W Dubensky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

7.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.

Authors:  Holly Starks; Kevin W Bruhn; Hao Shen; Ronald A Barry; Thomas W Dubensky; Dirk Brockstedt; David J Hinrichs; Darren E Higgins; Jeffrey F Miller; Martin Giedlin; H G Archie Bouwer
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

9.  Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication.

Authors:  Ashleigh Hodges; Katherine Sharrocks; Mariola Edelmann; Dilair Baban; Arnaud Moris; Olivier Schwartz; Hal Drakesmith; Kay Davies; Benedikt Kessler; Andrew McMichael; Alison Simmons
Journal:  Nat Immunol       Date:  2007-05-13       Impact factor: 25.606

10.  Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.

Authors:  Suha Saleh; Fiona Wightman; Saumya Ramanayake; Marina Alexander; Nitasha Kumar; Gabriela Khoury; Cândida Pereira; Damian Purcell; Paul U Cameron; Sharon R Lewin
Journal:  Retrovirology       Date:  2011-10-12       Impact factor: 4.602

View more
  5 in total

Review 1.  Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.

Authors:  Mansi Saxena; Nina Bhardwaj
Journal:  Curr Opin Immunol       Date:  2017-07-18       Impact factor: 7.486

2.  Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery.

Authors:  Xavier Chauchet; Dalil Hannani; Sophia Djebali; David Laurin; Benoit Polack; Jacqueline Marvel; Laurent Buffat; Bertrand Toussaint; Audrey Le Gouëllec
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

3.  Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.

Authors:  Mansi Saxena; Rachel L Sabado; Melissa La Mar; Hiroshi Mohri; Andres M Salazar; Hanqing Dong; Joel Correa Da Rosa; Martin Markowitz; Nina Bhardwaj; Elizabeth Miller
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

Review 4.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

Review 5.  Recent Advances in Lentiviral Vaccines for HIV-1 Infection.

Authors:  Thomas D Norton; Elizabeth A Miller
Journal:  Front Immunol       Date:  2016-06-21       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.